RU2695372C2 - Пролекарства антагониста NMDA - Google Patents

Пролекарства антагониста NMDA Download PDF

Info

Publication number
RU2695372C2
RU2695372C2 RU2016119493A RU2016119493A RU2695372C2 RU 2695372 C2 RU2695372 C2 RU 2695372C2 RU 2016119493 A RU2016119493 A RU 2016119493A RU 2016119493 A RU2016119493 A RU 2016119493A RU 2695372 C2 RU2695372 C2 RU 2695372C2
Authority
RU
Russia
Prior art keywords
phenyl
pyridin
compound
pharmaceutically acceptable
ethanamine
Prior art date
Application number
RU2016119493A
Other languages
English (en)
Russian (ru)
Other versions
RU2016119493A3 (enExample
RU2016119493A (ru
Inventor
Гуннар Нордвалль
Катарина ХЁГДИН
Пер Йонас МАЛЬМБОРГ
Анника Керс
Дирк ВАЙГЕЛЬТ
Питер БЕРНШТЕЙН
Майкл КУИРК
Балестра Майкл
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2016119493A publication Critical patent/RU2016119493A/ru
Publication of RU2016119493A3 publication Critical patent/RU2016119493A3/ru
Application granted granted Critical
Publication of RU2695372C2 publication Critical patent/RU2695372C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016119493A 2013-11-05 2014-10-30 Пролекарства антагониста NMDA RU2695372C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899903P 2013-11-05 2013-11-05
US61/899,903 2013-11-05
PCT/GB2014/053236 WO2015067923A1 (en) 2013-11-05 2014-10-30 Nmda antagonist prodrugs

Publications (3)

Publication Number Publication Date
RU2016119493A RU2016119493A (ru) 2017-12-07
RU2016119493A3 RU2016119493A3 (enExample) 2018-06-29
RU2695372C2 true RU2695372C2 (ru) 2019-07-23

Family

ID=51947383

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016119493A RU2695372C2 (ru) 2013-11-05 2014-10-30 Пролекарства антагониста NMDA

Country Status (25)

Country Link
US (4) US9822075B2 (enExample)
EP (3) EP3066091B1 (enExample)
JP (4) JP6479834B2 (enExample)
KR (2) KR102336426B1 (enExample)
CN (2) CN111187202B (enExample)
AR (1) AR098319A1 (enExample)
AU (1) AU2014345407B2 (enExample)
CA (1) CA2928004C (enExample)
CY (1) CY1121749T1 (enExample)
DK (1) DK3066091T3 (enExample)
ES (3) ES2733344T3 (enExample)
HR (2) HRP20191159T1 (enExample)
HU (2) HUE070532T2 (enExample)
LT (1) LT3066091T (enExample)
MX (2) MX394633B (enExample)
PL (2) PL4001272T3 (enExample)
PT (1) PT3066091T (enExample)
RS (2) RS58991B1 (enExample)
RU (1) RU2695372C2 (enExample)
SI (1) SI3066091T1 (enExample)
SM (1) SMT202500023T1 (enExample)
TR (1) TR201909632T4 (enExample)
TW (1) TW201609653A (enExample)
UY (1) UY35823A (enExample)
WO (1) WO2015067923A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
CN107578281B (zh) * 2017-08-31 2021-03-30 湖南大学 电子商务环境下用户优惠券行为预测方法及模型构建方法
BR112022025900A2 (pt) 2020-06-23 2023-01-10 Biohaven Therapeutics Ltd Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina
CN122421958A (zh) * 2023-12-22 2026-07-17 拜奥海芬治疗学有限公司 神经性障碍的组合治疗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1103794A3 (ru) * 1979-11-16 1984-07-15 Астра Лэкемедель Актиеболаг (Фирма) Способ получени производных пиридилаллиламина или их солей, или их смеси цис- и транс-изомеров, или индивидуальных изомеров
EP0356035B1 (en) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
RU2128650C1 (ru) * 1992-04-03 1999-04-10 Астра АБ (S)-α-ФЕНИЛ-2-ПИРИДИНЭТАНАМИН И ЕГО СОЛЬ С НЕОРГАНИЧЕСКИМИ КИСЛОТАМИ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ СУДОРОГ

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769466A (en) 1987-02-06 1988-09-06 Pennwalt Corporation 2-aminoacetamide pyridinyl derivatives
ES2142320T3 (es) 1991-10-30 2000-04-16 Astra Ab Derivados de 2-pirazinil-etilamina y su uso como productos farmaceuticos.
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
PA8525601A1 (es) 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
AU2002310409C1 (en) 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
CA2551859C (en) 2003-12-30 2011-10-04 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
EP1929030A2 (en) * 2005-09-08 2008-06-11 Shire LLC Prodrugs of t3 and t4 with enhanced bioavailability
CN101246417B (zh) 2007-02-13 2010-09-29 艾威梯科技(北京)有限公司 音频数据流输入/输出无间断软件切换的方法和系统
CA2710538A1 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2010017504A1 (en) * 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US9062094B2 (en) * 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US8580850B2 (en) * 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1103794A3 (ru) * 1979-11-16 1984-07-15 Астра Лэкемедель Актиеболаг (Фирма) Способ получени производных пиридилаллиламина или их солей, или их смеси цис- и транс-изомеров, или индивидуальных изомеров
EP0356035B1 (en) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
RU2128650C1 (ru) * 1992-04-03 1999-04-10 Астра АБ (S)-α-ФЕНИЛ-2-ПИРИДИНЭТАНАМИН И ЕГО СОЛЬ С НЕОРГАНИЧЕСКИМИ КИСЛОТАМИ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ СУДОРОГ

Also Published As

Publication number Publication date
HUE045001T2 (hu) 2019-12-30
CN105683180B (zh) 2020-01-21
EP4001272B1 (en) 2024-11-13
US20190152914A1 (en) 2019-05-23
EP3066091A1 (en) 2016-09-14
EP4001272C0 (en) 2024-11-13
KR20210148443A (ko) 2021-12-07
CA2928004C (en) 2022-04-12
ES2999064T3 (en) 2025-02-24
CN105683180A (zh) 2016-06-15
SI3066091T1 (sl) 2019-09-30
HUE070532T2 (hu) 2025-06-28
PT3066091T (pt) 2019-07-11
JP2021100950A (ja) 2021-07-08
HRP20191159T1 (hr) 2019-10-04
JP2016535098A (ja) 2016-11-10
CY1121749T1 (el) 2020-07-31
RU2016119493A3 (enExample) 2018-06-29
US12516023B2 (en) 2026-01-06
AU2014345407A1 (en) 2016-06-02
BR112016009949A8 (pt) 2020-04-14
JP7234278B2 (ja) 2023-03-07
AU2014345407B2 (en) 2018-10-18
US10815199B2 (en) 2020-10-27
SMT202500023T1 (it) 2025-03-12
RS66369B1 (sr) 2025-01-31
AR098319A1 (es) 2016-05-26
KR102336426B1 (ko) 2021-12-08
KR20160079094A (ko) 2016-07-05
RS58991B1 (sr) 2019-08-30
JP6856737B2 (ja) 2021-04-07
MX2020011946A (es) 2022-08-10
MX2016005567A (es) 2016-07-21
JP2019081781A (ja) 2019-05-30
JP6633233B2 (ja) 2020-01-22
US20180037550A1 (en) 2018-02-08
US9822075B2 (en) 2017-11-21
TR201909632T4 (tr) 2019-07-22
US20160280647A1 (en) 2016-09-29
MX377276B (es) 2025-03-07
PL3066091T3 (pl) 2019-10-31
RU2016119493A (ru) 2017-12-07
CN111187202B (zh) 2025-01-21
EP3066091B1 (en) 2019-04-03
ES2894903T3 (es) 2022-02-16
HRP20241784T1 (hr) 2025-02-28
LT3066091T (lt) 2019-07-10
MX394633B (es) 2025-03-24
CN111187202A (zh) 2020-05-22
JP2020055857A (ja) 2020-04-09
JP6479834B2 (ja) 2019-03-06
UY35823A (es) 2015-04-30
EP4001272A1 (en) 2022-05-25
US10207994B2 (en) 2019-02-19
TW201609653A (zh) 2016-03-16
US20210040039A1 (en) 2021-02-11
KR102469167B1 (ko) 2022-11-22
CA2928004A1 (en) 2015-05-14
WO2015067923A1 (en) 2015-05-14
DK3066091T3 (da) 2019-07-15
PL4001272T3 (pl) 2025-02-10
ES2733344T3 (es) 2019-11-28
EP3564234B1 (en) 2021-09-29
EP3564234A1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
JP7234278B2 (ja) Ｎｍｄａアンタゴニストプロドラッグ
JP7755347B2 (ja) 腎癌の標的治療のための新規化合物及び組成物
HK40076024A (en) Nmda antagonist prodrugs
HK40076024B (en) Nmda antagonist prodrugs
HK40014361A (en) Nmda antagonist prodrugs
HK40014361B (en) Nmda antagonist prodrugs
HK1226721B (en) Nmda antagonist prodrugs
HK1226721A1 (en) Nmda antagonist prodrugs
BR112016009949B1 (pt) Composto pró-fármaco antagonista de nmda, composição farmacêutica, e, uso de um composto
WO2025112215A1 (zh) 一种肽偶联t2毒素及其抗肿瘤应用